Roivant Sciences (ROIV) Receivables - Accured (2023 - 2026)
Roivant Sciences' (ROIV) quarterly Receivables - Accured came in at $19.6 million in Q1 2026, up 61.98% YoY from $12.1 million in Q1 2025, and up 61.98% on a QoQ basis from $12.1 million in Q1 2025.
Roivant Sciences (ROIV) Receivables - Accured (2023 - 2026) Analysis & Trends
Roivant Sciences (ROIV) has 4 years of Receivables - Accured data on file, last reported at $19.6 million in Q1 2026.
- Quarterly Receivables - Accured rose 61.98% year-over-year to $19.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $19.6 million (up 61.98% YoY) and the FY2026 annual result came in at $19.6 million, up 61.98% from the prior year.
- Receivables - Accured grew to $19.6 million in Q1 2026, from $12.1 million in the prior quarter.
- In the past five years, Receivables - Accured ranged from a high of $27.4 million in Q1 2024 to a low of $4.9 million in Q1 2023.
- A 4-year average of $17.8 million and a median of $19.3 million in 2023 frame the typical range for Receivables - Accured.
- Annual changes were most pronounced in 2024 — Receivables - Accured jumped 458.99% — and 2025, when it sank 55.91%.
- Tracing ROIV's Receivables - Accured over 4 years: stood at $18.9 million in 2023, then grew by 22.68% to $23.2 million in 2024, then slumped by 47.82% to $12.1 million in 2025, then jumped by 61.98% to $19.6 million in 2026.
- The last three Receivables - Accured figures came in at $19.6 million (Q1 2026), $12.1 million (Q1 2025), and $23.2 million (Q4 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Acc. Int. Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | 21.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 21.60 Mn |
| Jun 30, 2026 | 21.60 Mn |
| Mar 31, 2026 | 19.60 Mn |
| Mar 31, 2026 | 19.60 Mn |
| Mar 31, 2025 | 12.10 Mn |
| Mar 31, 2025 | 12.10 Mn |
| Dec 31, 2024 | 23.19 Mn |
| Dec 31, 2024 | 23.19 Mn |
| Sep 30, 2024 | 13.88 Mn |
| Sep 30, 2024 | 13.88 Mn |
| Jun 30, 2024 | 22.65 Mn |
| Jun 30, 2024 | 22.65 Mn |
| Mar 31, 2024 | 27.44 Mn |
| Mar 31, 2024 | 27.44 Mn |
| Dec 31, 2023 | 18.90 Mn |
| Dec 31, 2023 | 18.90 Mn |
| Mar 31, 2023 | 4.91 Mn |
| Mar 31, 2023 | 4.91 Mn |